- Home
- CRNC vs ERAS Comparison
CRNC vs ERAS Comparison
Compare CRNC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNC
- ERAS
- Stock Information
- Founded
- CRNC 2020
- ERAS 2018
- Country
- CRNC United States
- ERAS United States
- Employees
- CRNC N/A
- ERAS N/A
- Industry
- CRNC EDP Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CRNC Technology
- ERAS Health Care
- Exchange
- CRNC Nasdaq
- ERAS Nasdaq
- Market Cap
- CRNC 455.3M
- ERAS 484.4M
- IPO Year
- CRNC N/A
- ERAS 2021
- Fundamental
- Price
- CRNC $9.45
- ERAS $1.55
- Analyst Decision
- CRNC Hold
- ERAS Buy
- Analyst Count
- CRNC 5
- ERAS 6
- Target Price
- CRNC $10.20
- ERAS $3.83
- AVG Volume (30 Days)
- CRNC 2.6M
- ERAS 930.1K
- Earning Date
- CRNC 08-06-2025
- ERAS 08-12-2025
- Dividend Yield
- CRNC N/A
- ERAS N/A
- EPS Growth
- CRNC N/A
- ERAS N/A
- EPS
- CRNC N/A
- ERAS N/A
- Revenue
- CRNC $245,947,000.00
- ERAS N/A
- Revenue This Year
- CRNC N/A
- ERAS N/A
- Revenue Next Year
- CRNC $4.85
- ERAS N/A
- P/E Ratio
- CRNC N/A
- ERAS N/A
- Revenue Growth
- CRNC N/A
- ERAS N/A
- 52 Week Low
- CRNC $2.37
- ERAS $1.01
- 52 Week High
- CRNC $27.50
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- CRNC 44.34
- ERAS 50.88
- Support Level
- CRNC $9.03
- ERAS $1.33
- Resistance Level
- CRNC $10.18
- ERAS $1.66
- Average True Range (ATR)
- CRNC 0.58
- ERAS 0.09
- MACD
- CRNC -0.21
- ERAS -0.00
- Stochastic Oscillator
- CRNC 17.00
- ERAS 66.67
About CRNC Cerence Inc.
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.